Latest News

FTC complaint against major PBMs for anticompetitive rebating and insulin pricing.

Systemic barriers preventing HCV-infected people from accessing available cure.

ADA conflicts with state prescription drug affordability board operations.

Potential harms of state PDABs on HIV treatment access and ending the epidemic.

Unintended consequences of Inflation Reduction Act drug pricing provisions.

Declining HCV infections but persistent treatment barriers and disparities remain.

Medicaid's expanding role in addressing housing instability through Section 1115 waivers.

State-level PDAB implementation advancing despite patient advocacy concerns.

2024 federal healthcare policy priorities: 340B reform, PBM oversight, and telehealth.

CANN outlines organizational growth and 2024 policy priorities including state-level advocacy.

PDABs and upper-payment limits risk restricting medication access despite affordability intentions.

Payers face regulatory scrutiny for systematic coverage denials and prior authorization abuse.

SAMHSA releases Harm Reduction Framework for federal substance use programming and community approaches.

Mid-year policy update covering Medicaid unwinding, ACA preventive care, and public health funding.

Preview of 2023 federal regulatory priorities: Section 1557, IRA implementation, and prior authorization reform.

Pharmaceutical industry changes to 340B implementation impact pricing and accessibility for covered entities.

AMA survey: 93% of providers say prior authorizations delay care with 91% reporting negative clinical impact.

FDA reclassifies HCV testing to reduce regulatory burden and enable new test makers to enter market.

New CANN leadership reflects on mentorship and maintaining advocacy legacy following Bill Arnold's passing.

Explains why transparency in 340B operations is critical for program integrity and patient access.